Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

AstraZeneca CEO Pascal Soriot said on Thursday the company is likely to start a new global trial to measure how effective its coronavirus vaccine is, Bloomberg reports.

Why it matters: Following Phase 3 trials, Oxford and AstraZeneca said their vaccine was 90% effective in people who got a half dose followed by a full dose, and 62% effective in people who got two full doses.

  • “Now that we’ve found what looks like a better efficacy we have to validate this, so we need to do an additional study,” Soriot said, in his first interview since the University of Oxford announced data this week from the vaccine it's developing with AstraZeneca.

Soriot told Bloomberg that it would likely be another “international study, but this one could be faster because we know the efficacy is high so we need a smaller number of patients.”

  • Soriot does not expect the trial to affect regulatory approvals in the European Union and the U.K., although FDA clearance may take longer, he said.

Go deeper

Bryan Walsh, author of Future
Jan 23, 2021 - Health

Schools face an uphill battle to reopen during the pandemic

Illustration: Aïda Amer/Axios

President Biden's plan to accelerate the reopening of K-8 schools faces major challenges from a still out-of-control pandemic and more contagious coronavirus variants.

Why it matters: The longer American kids miss in-person schooling, the further they fall behind. But the uncertain state of the science on the role young children play in the pandemic continues to complicate efforts to reopen schools.

Latest James Bond movie release delayed for third time

An advertisement poster featuring Daniel Craig in the new James Bond movie "No Time to Die" in Bangkok, Thailand. Photo: Mladen Antonov/AFP via Getty Images

The release of the latest James Bond film, "No Time to Die," has been postponed for the third time as the coronavirus pandemic continues to devastate Hollywood.

The state of play: The film's release, initially scheduled for April 2020, was first postponed to November 2020, and then to April 2021. MGM said this week that movie's global debut will now be delayed until Oct. 8.